Antibiotics with Antiviral and Anti-Inflammatory Potential Against Covid-19: A Review. 2023

Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
Brain Cancer Research Core (BCRC), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

In Covid-19 cases, elderly patients in long-term care facilities, children younger than five years with moderate symptoms, and patients admitted to ICU or with comorbidities are at a high risk of coinfection, as suggested by the evidence. Thus, in these patients, antibiotic therapy based on empirical evidence is necessary. Finding appropriate antimicrobial agents, especially with antiviral and anti-inflammatory properties, is a promising approach to target the virus and its complications, hyper-inflammation, and microorganisms resulting in co-infection. Moreover, indiscriminate use of antibiotics can be accompanied by Clostridioides difficile colitis, the emergence of resistant microorganisms, and adverse drug reactions, particularly kidney damage and QT prolongation. Therefore, rational administration of efficient antibiotics is an important issue. The main objective of the present review is to provide a summary of antibiotics with possible antiviral activity against SARS-CoV-2 and anti-immunomodulatory effects to guide scientists for further research. Besides, the findings can help health professionals in the rational prescription of antibiotics in Covid-19 patients with a high risk of co-infection.

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D060085 Coinfection Simultaneous infection of a host organism by two or more pathogens. In virology, coinfection commonly refers to simultaneous infection of a single cell by two or more different viruses. Mixed Infection,Co-infection,Polymicrobial Infection,Secondary Infection,Secondary Infections,Co infection,Co-infections,Coinfections,Infection, Mixed,Infection, Polymicrobial,Infection, Secondary,Infections, Mixed,Infections, Polymicrobial,Infections, Secondary,Mixed Infections,Polymicrobial Infections

Related Publications

Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
December 2020, Phytotherapy research : PTR,
Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
April 2020, The Lancet. Infectious diseases,
Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
April 2021, Orvosi hetilap,
Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
December 2020, Archivos de bronconeumologia,
Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
March 2022, International journal of surgery (London, England),
Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
December 2020, Archivos de bronconeumologia,
Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
December 2020, Archivos de bronconeumologia,
Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
May 2023, Proceedings of the National Academy of Sciences of the United States of America,
Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
January 2021, Clinical epidemiology and global health,
Banafshe Abadi, and Mehran Ilaghi, and Yasamin Shahsavani, and Mahsa Faramarzpour, and Mohammad Bagher Oghazian, and Hamid-Reza Rahimi
January 2021, Drug discovery today,
Copied contents to your clipboard!